symbol |
FTSV |
会社名 | Forty Seven Inc (フォ―ティ―・セブン) |
分野(sector) |
Health Care
ヘルスケア
|
産業(industry) |
Major Pharmaceuticals
|
業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連(Health Care)
|
概要 |
事業概要 Forty Seven Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate 5F9 is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189 is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML) non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC) and ovarian cancer as both a monotherapy and in combination with other therapies such as rituximab and cetuximab. In addition to the 5F9 which is an antibody that binds to CD47 blocking its binding to SIRPa. フォ―ティ―・セブンは米国のバイオ医薬品企業。臨床段階で、がんに対する免疫治療の開発に従事する。同社は、マイクロファ―ジを活性化するための新しいチェックポイント療法に焦点を当てる。がんの治療に使用されるタンパク質CD47に対するヒト化lgG4サブクラス・モノクロ―ナル抗体を開発する。本社所在地はカリフォルニア州メンロ・パ―ク。 Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
|
本社所在地 | 1490 O?Brien Drive Suite A Menlo Park CA 94025 USA |
代表者氏名 | Mark McCamish マーク・マッカミッシュ |
代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者(CEO) |
電話番号 | +1 650-352-4150 |
設立年月日 | 2014年 |
市場名 | NASDAQ National Market System |
ipoyear | 2018年 |
従業員数 | - |
url | www.fortyseveninc.com |
nasdaq_url | https://www.nasdaq.com/symbol/ftsv |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -55.04900 |
終値(lastsale) | 13.75 |
時価総額(marketcap) | 426911182.5 |
時価総額 | 時価総額(百万ドル) 450.50770 |
売上高 | 売上高(百万ドル) 0.00000 |
企業価値(EV) | 企業価値(EV)(百万ドル) 541.89770 |
当期純利益 | 当期純利益(百万ドル) -51.90700 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Forty Seven Inc revenues was not reported. Net loss increased 45% to $31.5M. Higher net loss reflects Research and development increase of 34% to $24.5M (expense) General and administrative increase of 94% to $6.5M (expense) Stock-based Compensation in SGA increase from $137K to $750K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.73 to -$1.04. |